Influence of growth hormone therapy on the occurrence of a second neoplasm in survivors of childhood cancer
| العنوان: | Influence of growth hormone therapy on the occurrence of a second neoplasm in survivors of childhood cancer |
|---|---|
| المؤلفون: | Stéphanie Bolle, Ibrahima Diallo, Brice Fresneau, Charlotte Demoor-Goldschmidt, Hélène Pacquement, Isabelle Oliver-Petit, Nadia Haddy, Florent de Vathaire, Delphine Berchery, Cécile Thomas-Teinturier, Rodrigue S. Allodji, Cristina Veres |
| المصدر: | European Journal of Endocrinology. 183:471-480 |
| بيانات النشر: | Oxford University Press (OUP), 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Adult, Male, medicine.medical_specialty, Adolescent, Hormone Replacement Therapy, Endocrinology, Diabetes and Metabolism, 030209 endocrinology & metabolism, Context (language use), Gastroenterology, Cohort Studies, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Endocrinology, Cancer Survivors, Internal medicine, Meningeal Neoplasms, medicine, Humans, Young adult, Child, Aged, Retrospective Studies, Brain Neoplasms, Human Growth Hormone, business.industry, Infant, Newborn, Late effect, Case-control study, Infant, Cancer, Neoplasms, Second Primary, Retrospective cohort study, General Medicine, Middle Aged, medicine.disease, Case-Control Studies, Child, Preschool, 030220 oncology & carcinogenesis, Cohort, Female, France, Cranial Irradiation, medicine.symptom, Meningioma, business, Follow-Up Studies, Cohort study |
| الوصف: | Context: Growth hormone (GH) deficiency is a common late effect of cranial irradiation. However, concerns have been raised that GH treatment might lead to an increased risk of a second neoplasm (SN). Objective: To study the impact of GH treatment on the risk of SN in a French cohort of survivors of childhood cancer (CCS) treated before 1986. Design and setting: Cohort study and nested case–control study. Participants: Of the 2852 survivors, with a median follow-up of 26 years, 196 had received GH therapy (median delay from cancer diagnosis: 5.5 years). Main outcome measures: Occurrence of SN Results: In total, 374 survivors developed a SN, including 40 who had received GH therapy. In a multivariate analysis, GH treatment did not increase the risk of secondary non-meningioma brain tumors (RR: 0.6, 95% CI: 0.2–1.5, P = 0.3), secondary non-brain cancer (RR: 0.7, 95% CI: 0.4–1.2, P = 0.2), or meningioma (RR: 1.9, 95% CI: 0.9–4, P = 0.09). Nevertheless, we observed a slight non-significant increase in the risk of meningioma with GH duration: 1.6-fold (95% CI: 1.2–3.0) after an exposure of less than 4 years vs 2.3-fold (95% CI: 0.9–5.6) after a longer exposure (P for trend = 0.07) confirmed by the results of a case–control study. Conclusion: This study confirms the overall safety of GH use in survivors of childhood cancer, which does not increase the risk of a SN. The slight excess in the risk of meningioma in patients with long-term GH treatment is non-significant and could be due to difficulties in adjustment on cranial radiation volume/dose and/or undiagnosed meningioma predisposing conditions. |
| تدمد: | 1479-683X 0804-4643 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e9bc297d7608cfd80a9edff4a03d804Test https://doi.org/10.1530/eje-20-0369Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....4e9bc297d7608cfd80a9edff4a03d804 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 1479683X 08044643 |
|---|